Compare JRVR & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JRVR | CYBN |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.7M | 298.9M |
| IPO Year | 2005 | N/A |
| Metric | JRVR | CYBN |
|---|---|---|
| Price | $6.58 | $6.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $6.25 | ★ $74.50 |
| AVG Volume (30 Days) | 234.1K | ★ 651.1K |
| Earning Date | 11-03-2025 | 11-13-2025 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $646,580,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | $4.81 |
| 52 Week High | $6.89 | $10.73 |
| Indicator | JRVR | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | 66.69 | 61.51 |
| Support Level | $6.51 | $6.53 |
| Resistance Level | $6.89 | $7.06 |
| Average True Range (ATR) | 0.21 | 0.38 |
| MACD | 0.05 | 0.11 |
| Stochastic Oscillator | 74.87 | 74.08 |
James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure, and the Corporate and other segment consists of the management and treasury activities of holding companies, and equity compensation for the group.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.